ImageneBio (IMA)
Develops IMG-007 for autoimmune and inflammatory diseases.
Something off on this page? Send us feedback.
Develops IMG-007, a non-depleting anti-OX40 antibody for autoimmune and inflammatory diseases. The clinical-stage business is concentrated on advancing the program in atopic dermatitis and alopecia areata.
Develops IMG-007, a non-depleting, ADCC-silenced anti-OX40 monoclonal antibody designed to target the OX40 receptor. The clinical-stage program has completed proof-of-concept trials in atopic dermatitis and alopecia areata, with a Phase 2b study continuing in moderate-to-severe atopic dermatitis.
Formed through Ikena Oncology’s 2025 merger with Inmagene, the Nasdaq-listed issuer shifted from its oncology history to immunology, autoimmune, and inflammatory-disease development. Its public shares began trading as IMA after the transaction, and it is headquartered in San Diego.
Operations are concentrated around IMG-007's clinical development. Progress depends on clinical, regulatory, and financing outcomes disclosed by the company.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 21, 2026 | H.C. Wainwright | Initiate | Buy |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $136.2M · Total debt $1.9M · Total assets $152.0M · Shareholders' equity $142.1M
- Revenue
- $0
- Operating income
- −$11.8M
- Net income
- −$10.2M
No dividends on record.
| Institutions39 holders · as of Mar 31, 2026 | 47.18% | 5.36M shares | |
| Insiders10 holders · as of Aug 17, 2026 | 24.80% | 2.82M shares | |
| Otherremainder | 28.02% | 3.18M shares |
11.35M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Trails Edge Capital Partners, LPInstitution | 10.36% | 1.18M | 13Gfiled Apr 21, 2026 ↗ |
Jonathan Jian WangInsiderdirector | 9.82% | 1.12M | Form 4filed Aug 15, 2025 ↗ |
BVF Inc/ILInstitution | 9.78% | 1.11M | 13Fas of Mar 31, 2026 |
Blue Owl Capital Holdings LPInstitution | 8.45% | 959,337 | 13Fas of Mar 31, 2026 |
Cable Car Capital LLCInstitution | 6.65% | 754,749 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 17, 2026 | Robert B. Lally | officer: Principal Accounting Officer | −1,525 | $5.34 |
| Jul 16, 2026 | Robert B. Lally | officer: Principal Accounting Officer | −1,671 | $5.50 |
| Apr 14, 2026 | Orbimed Advisors LLC | director | +721,292 | $0.0010 |
| Apr 14, 2026 | David P. Bonita | director | +721,292 | $0.0010 |
| Dec 24, 2025 | Joseph P. Slattery | director | +16,000 | $5.99 |
- Sanofi (ADR)
Co-markets Dupixent, an approved IL-4Rα biologic for AD
- Regeneron
Co-markets Dupixent, an approved IL-4Rα biologic for AD
- AbbVie
Rinvoq is an approved oral JAK inhibitor for moderate-to-severe AD
- Eli Lilly
Markets Ebglyss, an approved IL-13 biologic for moderate-to-severe AD
- Pfizer
Cibinqo is an approved oral JAK1 treatment for atopic dermatitis
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ImageneBio | $5.01 | −0.20% | $55.9M | — | — | — | — |
| Sanofi (ADR) | $44.52 | +0.12% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| Regeneron | $851.82 | −0.02% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| AbbVie | $264.00 | +0.88% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Eli Lilly | $1,167.77 | +0.72% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Pfizer | $28.98 | −0.17% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Median | 38.9 | 15.6 | 5.7 | +11.2% |